Cipla Ltd (CIPL.BO) Key Developments | Reuters.com
Edition:
United States

Cipla Ltd (CIPL.BO)

CIPL.BO on Bombay Stock Exchange

489.00INR
6:26am EDT
Change (% chg)

Rs12.50 (+2.62%)
Prev Close
Rs476.50
Open
Rs479.90
Day's High
Rs491.40
Day's Low
Rs474.00
Volume
193,479
Avg. Vol
196,754
52-wk High
Rs748.00
52-wk Low
Rs458.25

Latest Key Developments (Source: Significant Developments)

Cipla Ltd board recommends dividend
Friday, 29 May 2015 08:55am EDT 

Cipla Ltd:Recommended payment of dividend of 2 Indian rupees per equity share (face value 2 Indian rupees per equity share) for the year 2014-1.Dividend, subject to the approval of shareholders, will be dispatched / credited on or after Sept. 01.  Full Article

Cipla Ltd's Cipla EU to acquire Duomed Produtos-Business Standard
Thursday, 9 Apr 2015 02:12am EDT 

Cipla Ltd:Said its UK subsidiary Cipla EU Ltd will acquire Brazilian firm Duomed Produtos Farmaceuticos for about 26 mln Indian Rupees-Business Standard.The deal has the approval of Brazilian health authority (ANVISA) and other regulatory authorities to import and distribute pharmaceutical products in Brazil, the filing said.The transaction is expected to be completed by end of May 2015.  Full Article

Cipla Ltd's Cipla (EU) Ltd to form JVC with Biopharm SPA-Business Standard
Friday, 13 Feb 2015 01:45am EST 

Cipla Ltd:Entered into an agreement with Biopharm SPA to form a joint venture company (JVC) in Algeria to manufacture and market respiratory products-Business Standard.Cipla (EU) Ltd, will hold a 40 per cent stake in the JV company while the remainder will be held by a Biopharm-led Algerian consortium.  Full Article

Cipla Ltd wins 188.95 million of Global Fund ARV Tender
Friday, 13 Feb 2015 12:05am EST 

Cipla Ltd:Announces that it has been awarded $188.95 million of Global Fund ARV Tender.Says that it has been selected as a ‘Panel Supplier’ for a supplier partnership agreement.Says the the contract is effective from Jan. 1 and will run for a period of three years.Says the supplies will begin from Q4 FY 2015.  Full Article

Cipla Ltd signs definitive agreement to acquire 60 pct stake of Jay Precision Pharmaceuticals Private Limited
Thursday, 12 Feb 2015 08:30am EST 

Cipla Ltd:Signs a definitive agreement to acquire 60 pct stake of Jay Precision Pharmaceuticals Private Limited, Mumbai, from the existing shareholders, for a cash consideration of 960 mln Indian Rupees.Jay Precision is an existing supplier of respiratory devices to Company and has a state of the art manufacturing facility at Vasai, Maharashtra.Considering Company's position in inhalation therapy, this transaction is aimed at integrating the value chain and will serve as platform for development of next generation respiratory devices.Pharmaceutical undertaking of Jay Precision Products (India) Private Limited was demerged into Jay Precision effective Jan. 01, 2014.Transaction is expected to be completed by end of this financial year, subject to completion of certain conditions.  Full Article

Cipla Ltd allots equity shares
Friday, 23 Jan 2015 08:09am EST 

Cipla Ltd:Allotted 39,083 equity shares of two Indian Rupees each pursuant to exercise of the stock options.  Full Article

Cipla Ltd's subsidiary to sell equity interest in Jiangsu Cdymax Pharmaceuticals Co. Ltd
Wednesday, 10 Dec 2014 12:23am EST 

Cipla Ltd:Says that Meditab Holdings Limited, Mauritius, a wholly owned subsidiary of the company, has entered into a definitive agreement.Says the agreement is to sell its entire 48.22 pct equity interest in Jiangsu Cdymax Pharmaceuticals Co. Ltd., China to an affiliate of one of the other shareholders of Jiangsu, for a total consideration of 18.5 million.  Full Article

Meda and Cipla sue Apotex to enforce Dymista patents
Wednesday, 3 Dec 2014 02:00am EST 

Meda AB:Says Meda Pharmaceuticals Inc and Cipla Ltd announced that they sued Apotex Inc. and Apotex Corp (Apotex) in Federal District Court in Delaware to enforce the Orange-Book listed patents covering Dymista (azelastine HCl/fluticasone propionate) Nasal Spray.In response to Apotex's submission to the US Food and Drug Administration of an Abbreviated New Drug Application, and accompanying Paragraph IV certification, seeking approval to market a generic version of Meda's Dymista prior to expiration of the Dymista patents.Says the Complaint was filed within 45 days of receiving Apotex's Paragraph IV certification notice, thus triggering an automatic stay preventing the FDA from approving Apotex's ANDA for 30 months from receipt of the notice, unless ordered otherwise by a district court.Meda has the exclusive licenses to U.S. Patent Nos. 8,163,723 and 8,168,620 covering the Dymista composition and its approved uses, which does not expire until 2026.Meda holds the New Drug Application (NDA) to manufacture and market Dymista in the US for the treatment of seasonal allergic rhinitis.Meda and Cipla are jointly represented by attorneys from Sterne, Kessler, Goldstein & Fox P.L.L.C. and Ashby & Geddes, PA.  Full Article

Cipla Ltd announces a distribution agreement with Serum Institute of India
Thursday, 20 Nov 2014 12:40am EST 

Cipla Ltd:Says it has signed a distribution agreement with Serum Institute of India.Says under the agreement, SII will develop and manufacture paediatric vaccined, Cipla will seek European medicines Agency approval and market the products in Europe.Says this collaboration with SII enables cipla to enter into the vaccines segment, continuing commitment to inclusive healthcare for the world.  Full Article

Cipla Ltd asks government to revoke Novartis patents on respiratory drug - Reuters
Wednesday, 29 Oct 2014 08:00pm EDT 

Cipla Ltd:Says it had requested the Indian government to revoke five patents held by Novartis AG on respiratory drug Onbrez, to boost its access in the Indian market - Reuters.Alleged that Novartis has had patents on the drug since 2008/09, but did not make it in India, and instead imported a negligible quantity from Switzerland, leading to a shortage of supply.Says it has potential to manufacture adequate quantities of the drug and make the same available in the country.  Full Article